SHELTON, Conn., June 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Eric J. Vandal has been named Vice President, Commercial Operations. Mr. Vandal will assume responsibility for developing and implementing commercialization and marketing strategies in support of Cara’s clinical development programs.
Help employers find you! Check out all the jobs and post your resume.
